Aug 26, 2020

Australian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19

Australian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19

Starpharma was recently featured in an article by Australian Manufacturing, a leading publication and resource for the manufacturing and industrial sector in Australia. The article noted Starpharma had undertaken a pilot manufacture for its SPL7013 antiviral nasal spray, which has been tested and confirmed to have potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The article also highlightsed SPL has identified a manufacturer and are currently compiling documentation in preparation for regulatory submission.

To read the full article click here.

 This contains certain forward-looking statements.